Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Ezetimibe and Atorvastatin Calcium Tablets (I), which will enhance the company's product line and market competitiveness [1][5]. Drug Registration Certificate Details - The drug registration certificate (Certificate No. 2025S03344) was issued by the National Medical Products Administration (NMPA) for Ezetimibe and Atorvastatin Calcium Tablets (I), which contains 10mg of Ezetimibe and 10mg of Atorvastatin Calcium per tablet [1][2]. - The drug is indicated for hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) and was first approved by the FDA in May 2013 [1][2]. R&D Investment - The total R&D investment for this drug has reached RMB 5.0458 million (unaudited) as of the date of the announcement [3]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Ezetimibe and Atorvastatin Calcium Tablets in China for the first half of 2025 was approximately RMB 8.64 million, with sales from urban public hospitals and county-level public hospitals accounting for RMB 6.74 million [4]. - Sales from urban community centers and township health clinics were RMB 1.77 million, while urban pharmacies and online pharmacies contributed RMB 0.13 million [4].

证券代码：601089 证券简称：福元医药 公告编号：临 2025-076 药品名称 药品通用名称：依折麦布阿托伐他汀钙片（Ⅰ） 英文名/拉丁名：Ezetimibe and Atorvastatin Calcium Tablets（Ⅰ） 剂型 片剂 注册分类 化学药品4类 规格 每片含依折麦布10mg与阿托伐他汀钙10mg（按 C₃₃H₃₅FN₂O₅计） 药品批准文号 国药准字H20255884 药品注册标准编号 YBH27552025 一、药品注册证书主要内容 | 处方药/非处方药 | 处方药 | | --- | --- | | 申请事项 | 药品注册（境内生产） | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规 批准注册，发给药品注册证书。质量标准、说 | | | 定，经审查，本品符合药品注册的有关要求， | | | 明书、标签及生产工艺照所附执行。药品生产 | | | 企业应当符合药品生产质量管理规范要求方可 | | | 生产销售。 | | 上市许可持有人 | 北京福元医药股份有限公司 | | 生产企业 | 北京福元医药股份有限公司 | 二、药品相关信息 依折麦布阿托伐他汀钙片（Ⅰ）由 O ...

Core Viewpoint - The approval of Ezetimibe Atorvastatin Calcium Tablets (I) by the National Medical Products Administration marks a significant milestone for the company, allowing it to produce and market the drug in China for treating high cholesterol and homozygous familial hypercholesterolemia (HoFH) [1] Company Summary - The company, Fuyuan Pharmaceutical (601089.SH), has received the drug registration certificate for Ezetimibe Atorvastatin Calcium Tablets (I) from the National Medical Products Administration [1] - The drug contains 10mg of Ezetimibe and 10mg of Atorvastatin Calcium per tablet [1] - The drug was developed by Organon and was first approved by the FDA in May 2013 [1] - The approval for the drug's market entry in China was granted in September 2023 [1] Industry Summary - Ezetimibe Atorvastatin Calcium Tablets (I) are indicated for the treatment of high cholesterol and homozygous familial hypercholesterolemia (HoFH) [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the production of Ezetimibe and Atorvastatin Calcium Tablets (I), marking a significant milestone for its product portfolio in the cholesterol management market [1] Company Summary - The approved drug, Ezetimibe and Atorvastatin Calcium Tablets (I), was developed by Organon and was first approved by the FDA in May 2013 [1] - The drug is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [1] - The company received the acceptance notice for the application on January 8, 2025, and has recently obtained the drug registration certificate from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation according to national policy regulations [1] Industry Summary - The approval of Ezetimibe and Atorvastatin Calcium Tablets (I) in China is part of a broader trend in the pharmaceutical industry focusing on cholesterol-lowering medications [1] - The market for cholesterol management drugs is expected to grow, driven by increasing awareness of cardiovascular diseases and the need for effective treatment options [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089) emphasizes its commitment to fair information disclosure by stating that it will disclose the number of shareholders in its periodic reports to ensure all investors receive equal access to company information [1] Group 1 - The company responded to investor inquiries on November 5 regarding its information disclosure practices [1] - Fuyuan Pharmaceutical aims to adhere to relevant laws and regulations in its reporting [1] - The company highlights the importance of equal information access for all investors [1]

Group 1 - The core viewpoint of the articles highlights the recent movements of large private equity firms in the stock market, particularly focusing on their significant holdings in various sectors such as computers, food and beverages, and electronics [1] - As of October 31, 35 large private equity firms have reported holdings in 203 stocks, with a total market value exceeding 700 billion yuan [1] - Gao Yi Asset, led by Qiu Guolu, has significant positions in 18 companies, with Hikvision (002415) being the largest holding valued at 8.826 billion yuan, despite a reduction of 58 million shares in the third quarter [1] - Another firm, Zhongyang Investment, maintained its position in Xinhecheng (002001) with 61.1781 million shares, valued at 1.458 billion yuan, while also entering new positions in several other stocks [1] Group 2 - Some large private equity firms have announced a suspension of new investments, such as Ningquan Asset, which will stop accepting new subscriptions from October 30, while existing investors can still make additional purchases [2] - In the third quarter, Ningquan Asset increased its holdings in Zhuming Technology (300232) by 6.5721 million shares and made new investments in Fuanna (002327) with 605.12 thousand shares [2] - Starstone Investment believes that the market still has internal driving forces, with short-term uncertainties affecting risk appetite, while medium-term uncertainties are expected to ease, indicating a potential continuation of a bull market [2]

Core Viewpoint - Fuyuan Pharmaceutical, a well-known domestic pharmaceutical company, focuses on drug formulation and medical devices, showcasing strong R&D capabilities and a diverse product line [1] Group 1: Business Performance - In Q3 2025, Fuyuan Pharmaceutical reported revenue of 2.521 billion yuan, ranking 28th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The company's net profit for the same period was 378 million yuan, placing it 22nd in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Fuyuan Pharmaceutical's debt-to-asset ratio was 22.82%, lower than the industry average of 35.26% and down from 23.55% in the previous year [3] - The company's gross profit margin stood at 65.95%, slightly down from 67.09% year-on-year but still above the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman and general manager, Huang He, received a salary of 1.68 million yuan in 2024, an increase of 242,900 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.39% to 22,700, while the average number of circulating A-shares held per shareholder increased by 3.51% to 21,200 [5] Group 5: Research and Development - In the first half of 2025, Fuyuan Pharmaceutical's revenue was 1.634 billion yuan, a year-on-year decline of 1.3%, with a net profit of 268 million yuan, down 7.83% [6][7] - The company has a rich pipeline of generic drugs, with 11 applications submitted for approval in the first half of the year, and is advancing research on small nucleic acid drugs [6][7]

Group 1 - The core point of the article highlights the recent performance of Fuyuan Pharmaceutical, which saw a 5.36% increase in stock price, reaching 22.98 yuan per share, with a trading volume of 100 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 11.03 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is primarily engaged in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, E Fund's healthcare mixed fund A (110023) entered the list in the third quarter, holding 2.5638 million shares, which accounts for 0.53% of the circulating shares, with an estimated floating profit of approximately 2.9996 million yuan [2] - E Fund's healthcare mixed fund A (110023), established on January 28, 2011, has a latest scale of 3.802 billion yuan, with a year-to-date return of 31.25%, ranking 3013 out of 8154 in its category, and a one-year return of 22.68%, ranking 3972 out of 8046 [2] - The fund manager, Yang Zhenshao, has been in the position for 9 years and 75 days, managing a total fund asset size of 9.816 billion yuan, with the best fund return during his tenure being 209.89% and the worst being -14.74% [2]

Core Viewpoint - Fuyuan Pharmaceutical (601089) reported that its current business operations are normal and all business segments are progressing steadily [1] Company Summary - The company is actively engaging with investors and providing updates on its operational status [1] - Fuyuan Pharmaceutical emphasizes stability in its business activities, indicating a positive outlook for ongoing operations [1]

北京福元医药股份有限公司 关于取消监事会、增加董事会席位、修订《公司章程》 及修订、制定部分治理制度的公告 证券代码：601089 证券简称：福元医药 公告编号：临2025-071 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京福元医药股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开了 第三届董事会第三次会议和第三届监事会第三次会议，分别审议通过了《关于取消 监事会、增加董事会席位、修订<公司章程>并办理工商变更登记的议案》。现将有 关情况公告如下： 一、取消监事会 公司拟不再设置监事会，同时免去监事职务，监事会的职权由董事会审计委员会 行使。同时，公司《监事会议事规则》相应废止。 二、增加董事会席位 公司为进一步提高董事会决策的科学性和有效性，拟新增 1 名职工代表董事， 将董事会席位由 8 名增加至 9 名，独立董事 3 名保持不变，非独立董事由 5 名增加 至 6 名。 三、修订《公司章程》 根据《中华人民共和国公司法》《上市公司章程指引》等相关法律法规和规范 性文件的规定，结合公司实际情况 ...